Neuphoria Advances BNC210 to Phase 3 for SAD, PTSD; Nabs $15M Merck Milestone

TL;DR

**Neuphoria's BNC210 is a high-risk, high-reward bet, with promising Phase 2 PTSD data and a Merck partnership, but its future hinges entirely on successful Phase 3 SAD and PTSD trials.**

AI Summary

Neuphoria Therapeutics Inc. (NEUP) is a clinical-stage biotechnology company focused on neuropsychiatric disorders. The company is advancing its lead drug candidate, BNC210, for the acute treatment of Social Anxiety Disorder (SAD) and chronic treatment of Post-Traumatic Stress Disorder (PTSD). For SAD, Neuphoria initiated the Phase 3 AFFIRM-1 trial in July 2024, targeting 332 adult patients, with topline results expected in early Q4 2025. For PTSD, the Phase 2b ATTUNE trial met its primary endpoint in September 2023, showing a statistically significant change in CAPS-5 score (p=0.048) and improvements in depressive symptoms (p=0.041) and sleep (p=0.039). A Phase 2b/3 SYMPHONY trial for PTSD is planned for H1 2026. Neuphoria also received a $15 million milestone payment from Merck & Co., Inc. on March 19, 2025, for the initiation of a Phase 2 trial for MK-1167 in Alzheimer's disease, and an A$1 million milestone payment from Carina Biotech on October 30, 2024, for a Phase 1 clinical trial initiation.

Why It Matters

Neuphoria's progress with BNC210 addresses a significant unmet medical need for over 27 million patients suffering from SAD and PTSD, potentially offering a new therapeutic option without the severe side effects of current treatments like benzodiazepines and antidepressants. Successful clinical trials could disrupt the existing market dominated by older drugs, benefiting patients with faster onset and better tolerability. For investors, the advancement of BNC210 into late-stage trials and the $15 million milestone payment from Merck validate Neuphoria's pipeline and strategic partnerships, signaling potential future revenue streams and reducing development risk. This could intensify competition in the neuropsychiatric drug market, pushing other pharmaceutical companies to innovate.

Risk Assessment

Risk Level: high — Neuphoria is a clinical-stage biotechnology company with no approved products and relies heavily on the success of its lead candidate, BNC210, in ongoing and planned Phase 3 trials. The Phase 2 PREVAIL trial for SAD missed its primary endpoint, indicating significant development risk, and the company explicitly states a 'lack of operating history and need for additional capital' in its forward-looking statements.

Analyst Insight

Investors should closely monitor the topline results from the Phase 3 AFFIRM-1 trial for SAD, expected in early Q4 2025, as this will be a critical catalyst for NEUP's valuation. Given the high-risk profile, consider a speculative position only if comfortable with significant volatility and the potential for substantial capital loss if trials fail.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

N/A

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

N/A

Key Numbers

• $15 million — Milestone payment from Merck (Received on March 19, 2025, for MK-1167 Phase 2 initiation)
• A$1 million — Milestone payment from Carina Biotech (Received on October 30, 2024, for CNA3103 Phase 1 initiation)
• 27 million — Patients in the United States (Suffering from SAD and PTSD, representing significant unmet medical need)
• 332 — Adult patients (Target enrollment for Phase 3 AFFIRM-1 trial for SAD)
• 212 — Enrolled patients (In Phase 2b ATTUNE trial for PTSD)
• $5,213,998 — Aggregate market value of Common Stock held by non-affiliates (As of December 31, 2024)
• 2,357,613 — Shares of Common Stock outstanding (As of September 29, 2025)
• Q4 2025 — Expected topline results (For Phase 3 AFFIRM-1 trial in SAD)
• H1 2026 — Planned initiation (For Phase 3 AFFIRM-2 trial in SAD and Phase 2b/3 SYMPHONY trial in PTSD)

Key Players & Entities

• Neuphoria Therapeutics Inc. (company) — Registrant and clinical-stage biotechnology company
• BNC210 (drug) — Lead drug candidate for SAD and PTSD
• Merck & Co., Inc. (company) — Strategic partner, paid $15 million milestone
• Carina Biotech (company) — IP license agreement partner, paid A$1 million milestone
• FDA (regulator) — Food and Drug Administration, provided guidance for BNC210 trials
• MK-1167 (drug) — 7 receptor PAM in Phase 2 for Alzheimer's disease
• Nasdaq Stock Market LLC (regulator) — Exchange where NEUP Common Stock is registered
• Bionomics Limited (company) — Former name of Neuphoria Therapeutics Inc. prior to re-domiciliation

FAQ

Risk Factors

• FDA Approval Uncertainty [high — regulatory]: Neuphoria's lead drug candidate, BNC210, faces significant regulatory hurdles. While the company had a positive End-of-Phase 2 meeting with the FDA for BNC210 in SAD, the success of the upcoming Phase 3 AFFIRM-1 trial is critical for further advancement. The company has also experienced setbacks, such as the Phase 2 PREVAIL trial for SAD missing its primary endpoint, highlighting the inherent unpredictability of clinical trials and regulatory review processes.
• Dependence on Future Financing [high — financial]: As a clinical-stage biotechnology company, Neuphoria relies heavily on external funding to support its research and development activities. The company's ability to continue operations and advance its pipeline, including the BNC210 program and preclinical assets, is contingent upon securing additional capital through equity financings, debt financings, or strategic partnerships. Failure to obtain necessary funding could significantly impact its ability to achieve its business objectives.
• Competition in Neuropsychiatric Disorders [medium — market]: The market for treatments for neuropsychiatric disorders, including SAD and PTSD, is competitive. Current pharmacological treatments include antidepressants and benzodiazepines, and there are ongoing efforts by other companies to develop novel therapies. Neuphoria's BNC210 must demonstrate clear advantages in efficacy, safety, and tolerability over existing treatments and emerging competitors to gain market share.
• Clinical Trial Execution Risks [high — operational]: The success of Neuphoria's drug development programs hinges on the successful execution of clinical trials. The Phase 3 AFFIRM-1 trial for SAD, targeting 332 patients, and the planned Phase 2b/3 SYMPHONY trial for PTSD, are complex undertakings. Delays in patient enrollment, unexpected adverse events, or failure to meet trial endpoints could significantly impact the company's timeline, financial resources, and overall development strategy.
• Reliance on Milestone Payments [medium — financial]: Neuphoria has received milestone payments from strategic partners, such as the $15 million from Merck for MK-1167 and A$1 million from Carina Biotech for CNA3103. While these payments provide crucial non-dilutive funding, the company's financial health is also dependent on the successful progression of these partnered programs and the achievement of future milestones, which are not guaranteed.

Industry Context

Neuphoria operates in the highly competitive biotechnology sector, specifically focusing on the development of novel therapies for neuropsychiatric disorders. The market for treatments for conditions like Social Anxiety Disorder (SAD) and Post-Traumatic Stress Disorder (PTSD) is characterized by significant unmet medical needs and a lack of recent FDA-approved therapies, creating opportunities for innovative treatments. However, the landscape also includes established pharmaceutical companies and numerous emerging biotechs vying for market share with diverse approaches.

Regulatory Implications

Neuphoria's drug development pipeline is subject to stringent regulatory oversight by agencies like the FDA. Successful navigation of clinical trial phases, adherence to Good Clinical Practice (GCP) standards, and robust data generation are paramount for regulatory approval. The company's reliance on BNC210 means that any adverse regulatory decisions or significant delays in the approval process could severely impact its future prospects.

What Investors Should Do

1. Monitor Phase 3 AFFIRM-1 trial results
2. Track progress of Merck partnership (MK-1167)
3. Assess cash burn and future financing needs
4. Evaluate competitive landscape for SAD and PTSD treatments

Key Dates

• 2024-10-30: Carina Biotech milestone payment — Received A$1 million for Phase 1 clinical trial initiation of CNA3103, providing non-dilutive funding and validating early-stage progress.
• 2025-03-19: Merck & Co. milestone payment — Received $15 million for the initiation of a Phase 2 trial for MK-1167 in Alzheimer's disease, a significant validation of the partnership and a substantial cash infusion.
• 2025-07-01: Phase 3 AFFIRM-1 trial initiation — Initiated the pivotal trial for BNC210 in Social Anxiety Disorder (SAD), targeting 332 adult patients, a critical step towards potential FDA approval.
• 2025-10-01: Expected topline results for AFFIRM-1 — Anticipated results from the Phase 3 SAD trial will be a key catalyst for investors, determining the drug's potential for regulatory submission and commercialization.
• 2026-01-01: Planned initiation of Phase 3 AFFIRM-2 trial — Planned initiation of a second Phase 3 trial for BNC210 in SAD, indicating continued commitment to the indication and potentially supporting a broader regulatory submission.
• 2026-01-01: Planned initiation of Phase 2b/3 SYMPHONY trial — Planned initiation of a combined Phase 2b/3 trial for BNC210 in PTSD, building on positive Phase 2b results and advancing towards potential approval for chronic PTSD treatment.

Glossary

Selective negative allosteric modulator of the a7 nicotinic acetylcholine receptor

A type of drug that binds to a receptor at a site different from the main binding site, altering the receptor's shape and reducing its activity. Specifically, it targets the alpha-7 nicotinic acetylcholine receptor, which plays a role in neurotransmission. (This describes the mechanism of action for Neuphoria's lead drug candidate, BNC210, and is central to its therapeutic approach for neuropsychiatric disorders.)

Social Anxiety Disorder (SAD)

A mental health condition characterized by significant anxiety and fear in social situations, leading to avoidance of such situations. (SAD is one of the primary indications for Neuphoria's lead drug candidate, BNC210, highlighting a key area of focus for the company.)

Post-Traumatic Stress Disorder (PTSD)

A mental health condition that's triggered by a terrifying event, either experiencing it or witnessing it. Symptoms may include flashbacks, nightmares, and severe anxiety, as well as uncontrollable thoughts about the event. (PTSD is another key indication for BNC210, representing a significant unmet medical need that Neuphoria aims to address.)

Subjective Units of Distress Scale (SUDS)

A self-report measure used in therapy to assess the level of distress or anxiety a person is experiencing, typically on a scale of 0 to 100. (SUDS was the primary endpoint in the Phase 2 PREVAIL trial for BNC210 in SAD, and its measurement is crucial for evaluating the drug's efficacy in reducing anxiety.)

Nicotinic acetylcholine receptor

A class of receptors found in the central and peripheral nervous system that are activated by the neurotransmitter acetylcholine. The alpha-7 subtype (a7) is implicated in various cognitive and emotional processes. (The a7 receptor is the target of BNC210, and understanding its role is key to understanding Neuphoria's drug development strategy.)

Year-Over-Year Comparison

Information comparing key metrics to the previous year, such as revenue growth, margin changes, and new risks, is not available from the provided text. The 10-K filing typically includes a comparative analysis of financial statements and operational highlights from the prior fiscal year, which would be necessary for this comparison.

Key Financial Figures

• $0.00001 — nge on which registered Common Stock, $0.00001 par value per share NEUP The Nasdaq
• $15 million — March 19, 2025, the Company received a $15 million milestone payment from Merck. The payme
• $450 million — Neuphoria is eligible to receive up to $450 million in additional research and commercial m
• $118 million — ense, we are eligible to receive up to A$118 million in certain development, regulatory and
• $1 million — to the Company in the gross amount of A$1 million under the terms of the Carina Biotech L

Filing Documents

• neup-20250630.htm (10-K) — 3428KB
• neup-ex23_1.htm (EX-23.1) — 5KB
• neup-ex31_1.htm (EX-31.1) — 17KB
• neup-ex31_2.htm (EX-31.2) — 18KB
• neup-ex32_1.htm (EX-32.1) — 11KB
• neup-ex32_2.htm (EX-32.2) — 11KB
• img260795455_0.jpg (GRAPHIC) — 182KB
• img260795455_1.jpg (GRAPHIC) — 129KB
• img260795455_2.jpg (GRAPHIC) — 137KB
• img260795455_3.jpg (GRAPHIC) — 91KB
• img260795455_4.jpg (GRAPHIC) — 658KB
• img260795455_5.jpg (GRAPHIC) — 42KB
• img260795455_6.jpg (GRAPHIC) — 57KB
• img260795455_7.jpg (GRAPHIC) — 79KB
• img260795455_8.jpg (GRAPHIC) — 79KB
• img260795455_9.jpg (GRAPHIC) — 160KB
• img260795455_10.jpg (GRAPHIC) — 55KB
• img260795455_11.jpg (GRAPHIC) — 59KB
• img260795455_12.jpg (GRAPHIC) — 117KB
• img260795455_13.jpg (GRAPHIC) — 161KB
• img260795455_14.jpg (GRAPHIC) — 33KB
• img260795455_15.jpg (GRAPHIC) — 59KB
• 0001193125-25-223338.txt ( ) — 16630KB
• neup-20250630.xsd (EX-101.SCH) — 1393KB
• neup-20250630_htm.xml (XML) — 1830KB

Business

Business 1 Item 1A.

Risk Factors

Risk Factors 37 Item 1B. Unresolved Staff Comments 84 Item 1C. Cybersecurity 84 Item 2.

Properties

Properties 85 Item 3.

Legal Proceedings

Legal Proceedings 85 Item 4. Mine Safety Disclosures 85 PART II Item 5. Market for Registrant's Common Equity, Related shareholder Matters and Issuer Purchases of Equity Securities 86 Item 6. [Reserved] 86 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 87 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 95 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 97 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 97 Item 9A.

Controls and Procedures

Controls and Procedures 97 Item 9B. Other Information 98 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 98 PART III Item 10. Directors, Executive Officers and Corporate Governance 99 Item 11.

Executive Compensation

Executive Compensation 104 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related shareholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related shareholder Matters 111 Item 13. Certain Relationships and Related Transactions, and Director Independence 112 Item 14. Principal Accounting Fees and Services 112 PART IV Item 15. Exhibits, Financial Statement Schedules 114 Item 16. Form 10-K Summary 115

Signatures

Signatures 116 i Basis of Presentation Neuphoria Therapeutics Inc. is a Delaware corporation ("Neuphoria") listed on the Nasdaq Global Market. We were formally known as Bionomics Limited ("Bionomics") an Australian company that on October 1, 2024 entered into a Scheme Implementation Agreement with Neuphoria to re-domicile from Australia to the State of Delaware pursuant to a Scheme of Arrangement under Australian law. On December 23, 2024, the re-domiciliation of Bionomics was implemented and effectuated in accordance with the Scheme Implementation Agreement, as amended. As a result, (i) holders of ordinary shares of Bionomics received one share of our common stock for every 2,160 ordinary shares of Bionomics held on the Scheme record date; (ii) holders of Bionomics' American Depositary Shares ("ADS") with each ADS representing 180 ordinary shares of Bionomics, received one share of Neuphoria's common stock for every 12 ADSs held on the Scheme record date; and (iii) we became the successor issuer to Bionomics. Prior to our redomiciliation, since July 1, 2024, we had been reporting as a domestic U.S. issuer on SEC Forms 10-K, 10-Q, and 8-K. The terms "we," "our," "us" and the "Company" in this Annual Report on Form 10-K refer to Neuphoria Therapeutics Inc. and its consolidated subsidiaries after December 23, 2024 and Bionomics and its consolidated subsidiaries on and prior to December 23, 2024, unless otherwise specified. When we refer to "you," we mean the potential holders of the applicable series of securities: "shares" or "ordinary shares" refers to our ordinary shares prior to December 23, 2024; "shares of common stock" refers to our common stock, par value $0.00001 per share beginning December 24, 2024; "ADSs" refers to American Depositary Shares, each of which represented 180 ordinary shares prior to December 23, 2024; and "ADRs" refers to American Depositary Receipts, which evidence the ADSs. We use our registered and unregistered trademar

Business

Item 1. Business. Overview We are a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. Neuphoria is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the 7 nicotinic acetylcholine ("ACh") receptor ("a7 receptor") for the acute, "as needed" treatment of social anxiety disorder ("SAD") and for chronic treatment of post-traumatic stress disorder ("PTSD"). There remains a significant unmet medical need for the over 27 million patients in the United States alone suffering from SAD and PTSD. BNC210 is a first-of-its-kind, well-tolerated, broad spectrum anti-anxiety experimental therapeutic, designed to restore neurotransmitter balance in relevant brain areas, providing rapid relief from stress and anxiety symptoms without the common pitfalls of sedation, cognitive impairment, or addiction. In addition, Neuphoria has a strategic partnership with Merck & Co., Inc., known as Merck outside the United States and Canada, with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer's disease and other central nervous system ("CNS") conditions. Neuphoria's pipeline also includes the 7 nicotinic acetylcholine receptor next generation and the Kv3.1/3.2 preclinical programs, both in the lead optimization development stage. Current pharmacological treatments include certain antidepressants and benzodiazepines, and there have been no new Food and Drug Administration ("FDA") approved therapies in these indications in nearly two decades. These existing treatments have multiple shortcomings, such as a slow onset of action of antidepressants, and significant side effects of both classes of drugs, including abuse liability, addiction potential and withdrawal symptoms. BNC210 has been observed in our clinical trials to have a fast onset of action and clinical activity without the limiti

View Full Filing

View this 10-K filing on SEC EDGAR